Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy, Biologic therapy.

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:4City/State/Province:Madrid
Treatments:Chemotherapy, Biologic therapyHospital:Hospital General Universitario Gregorio Marañón
Drugs:Journal:Link
Date:Nov 2010

Description:

Patients:
This study involved 46 patients with metastatic colorectal carcinoma who had not received prior chemotherapy. The median patient age was 64 years (range of 39-80), and 46% were male.

Treatment:
Patients were treated with a combination of the biologic therapy agent bevacizumab (an antibody that blocks a protein involved in cancer cell growth) and the chemotherapy agents irinotecan and capecitabine.

Toxicities:
The maximum reported toxicity level was grade 4. Grade 3/4 adverse events included alopecia (in 13% of patients), asthenia (weakness, 7%), diarrhea (7%), and nausea (9%).

Results:
The median progression-free survival for this study was 12.3 months. The median overall survival was 23.7 months.

Support:
This study was supported by Roche, makers of bevacizumab (brand name: Avastin).

Correspondence: Dr P Garcia-Alfonso; email: [email protected]



Back